Literature DB >> 10993774

Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs.

M Behrends1, R Schulz, H Post, A Alexandrov, S Belosjorow, M C Michel, G Heusch.   

Abstract

The importance of the activation of mitogen-activated protein kinases (MAPK) for the cardioprotection achieved by ischemic preconditioning (IP) is still controversial. We therefore measured infarct size and p38, extracellular signal-regulated kinase (ERK), and c-Jun NH(2)-terminal kinase (JNK) MAPK phosphorylation (by biopsies) in enflurane-anesthetized pigs. After 90 min low-flow ischemia and 120 min reperfusion, infarct size averaged 18.3 +/- 12.4 (SD)% (group 1, n = 14). At similar subendocardial blood flows, IP by 10 min ischemia and 15 min reperfusion (group 2, n = 14) reduced infarct size to 6.2 +/- 5.1% (P < 0.05). An inconsistent increase in p38, ERK, and p54 JNK phosphorylation (by Western blot) was found during IP; p46 JNK phosphorylation increased with the subsequent reperfusion. At 8 min of the sustained ischemia, p38, ERK, and p54 JNK phosphorylation were increased with no difference between groups (medians: p38: 207% of baseline in group 1 vs. 153% in group 2; ERK: 142 vs. 144%; p54 JNK: 171 vs. 155%, respectively). MAPK phosphorylation and reduction of infarct size by IP were not correlated, thus not supporting the concept of a causal role of MAPK in mediating cardioprotection by IP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993774     DOI: 10.1152/ajpheart.2000.279.3.H1111

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

Review 1.  The role of myocardial ischaemic preconditioning during beating heart surgery: biological aspect and clinical outcome.

Authors:  Efstratios Apostolakis; Nikolaos G Baikoussis; Nikolaos A Papakonstantinou
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15

Review 2.  Systemic adiponectin malfunction as a risk factor for cardiovascular disease.

Authors:  Wayne Bond Lau; Ling Tao; Yajing Wang; Rong Li; Xin L Ma
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

3.  Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms.

Authors:  Wei Yi; Yang Sun; Erhe Gao; Xufeng Wei; Wayne Bond Lau; Qijun Zheng; Yajing Wang; Yuexing Yuan; Xiaoliang Wang; Ling Tao; Rong Li; Walter Koch; Xin-Liang Ma
Journal:  Antioxid Redox Signal       Date:  2011-04-11       Impact factor: 8.401

4.  AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings.

Authors:  Yanqing Zhang; Jianli Zhao; Rui Li; Wayne Bond Lau; Yue-Xing Yuan; Bin Liang; Rong Li; Er-He Gao; Walter J Koch; Xin-Liang Ma; Ya-Jing Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-02       Impact factor: 4.310

5.  Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury.

Authors:  Yajing Wang; Wayne Bond Lau; Erhe Gao; Ling Tao; Yuexing Yuan; Rong Li; Xiaoliang Wang; Walter J Koch; Xin-Liang Ma
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-22       Impact factor: 4.310

Review 6.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

7.  Effect of p38 MAP kinases on contractility and ischemic injury in intact heart.

Authors:  H R Cross; M Li; B G Petrich; E Murphy; Y Wang; Charles Steenbergen
Journal:  Acta Physiol Hung       Date:  2009-09

8.  Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure.

Authors:  Weihua Zhang; Vijayan Elimban; Mohinder S Nijjar; Suresh K Gupta; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2003

9.  Lymphotoxin-α is a novel adiponectin expression suppressor following myocardial ischemia/reperfusion.

Authors:  Wayne Bond Lau; Yanqing Zhang; Jianli Zhao; Baojiang Liu; Xiaoliang Wang; Yuexing Yuan; Theodore A Christopher; Bernard Lopez; Erhe Gao; Walter J Koch; Xin L Ma; Yajing Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-29       Impact factor: 4.310

10.  Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion.

Authors:  Eric N Churchill; Julio C Ferreira; Patricia C Brum; Luke I Szweda; Daria Mochly-Rosen
Journal:  Cardiovasc Res       Date:  2009-10-10       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.